Shares of Gossamer Bio (NASDAQ:GOSS) traded higher on Wednesday after UBS upgraded the California-based biotech to Buy from Neutral, citing an “underappreciated” late-stage data catalyst related to the company’s lead asset, seralutinib. The upgrades come at a time when a ...